MétaCan
Menu
Back to cohort
Record W4413001967 · doi:10.1016/j.ahj.2025.07.071

PRevention of sudden cardiac death aFter myocardial infarction by defibrillator implantation: Design and rationale of the PROFID EHRA randomized clinical trial

2025· article· en· W4413001967 on OpenAlexaff
Nikolaos Dagres, C P Gale, Ramesh Nadarajah, Serge Bovéda, José Luís Merino, Jens Cosedis Nielsen, Paulus Kirchhof, Valentina Kutyifa, Miloš Táborský, Holger Thiele, Jan G.P. Tijssen, Atul Verma, Tom De Potter, Frieder Braunschweig, Béla Merkely, Philipp Sommer, Kevin Vernooy, Mahmoud Suleiman, Helmut Pürerfellner, Gerhard Hindricks

Bibliographic record

VenueAmerican Heart Journal · 2025
Typearticle
Languageen
FieldMedicine
TopicCardiac pacing and defibrillation studies
Canadian institutionsMcGill University Health Centre
FundersBiosense WebsterHorizon 2020Medical Research CouncilDaiichi Sankyo EuropeEuropean CommissionSanofiDeutsches Zentrum für Herz-KreislaufforschungHorizon 2020 Framework ProgrammeBoston Scientific CorporationNovo NordiskBristol-Myers SquibbAstraZenecaUniversität HamburgMicroPortDeutsche ForschungsgemeinschaftFondation LeducqAmgen
KeywordsMedicineMyocardial infarctionSudden cardiac deathCardiologyVentricular fibrillationInternal medicineSudden deathImplantable cardioverter-defibrillatorClinical trialRandomized controlled trial

Abstract

fetched live from OpenAlex

BACKGROUND: Randomized clinical trials from over 20 years ago demonstrated that an implantable cardioverter defibrillator (ICD) improved survival for patients with severely reduced left ventricular ejection fraction (LVEF) after myocardial infarction (MI) compared with optimal medical therapy (OMT) alone. Since then advances in therapy have led to the reduction in the incidence of sudden cardiac death (SCD) in this population, whilst complication rates from ICD implantation are still substantial. OBJECTIVES: To determine whether OMT without ICD implantation is not inferior to OMT with ICD implantation with respect to all-cause mortality. DESIGN: The PROFID EHRA trial is an investigator-driven, prospective, parallel-group, randomized, open-label, blinded outcome assessment (PROBE), multi-center, noninferiority trial without dedicated investigational medical device (Proof of Strategy Trial) with 2 groups with 1:1 randomization. PROFID-EHRA will recruit approximately 3,595 patients with documented history of MI at least 3 months prior, LVEF ≤35%, on OMT for at least 3 months, and with New York Heart Association class II or III, who will be randomized to OMT or OMT plus ICD, to collect 374 first primary outcome events within a median observation period of around 28 months from about 180 clinical sites in an estimated 13 countries. The primary outcome is time from randomization to the occurrence of all-cause death. Secondary outcomes include time from randomization to death from cardiovascular causes, to SCD, to first hospital readmission for cardiovascular causes after date of randomization, the average length of hospital stay during follow-up, and quality of life trajectories. CLINICAL TRIAL: Trials.gov NCT05665608.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.067
metaresearch head score (Gemma)0.058
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Protocol · Consensus signal: Protocol
Teacher disagreement score0.067
Threshold uncertainty score0.352

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0670.058
Meta-epidemiology (narrow)0.0050.002
Meta-epidemiology (broad)0.0070.004
Bibliometrics0.0020.002
Science and technology studies0.0010.004
Scholarly communication0.0040.003
Open science0.0030.002
Research integrity0.0080.005
Insufficient payload (model declined to judge)0.0100.003

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.037
GPT teacher head0.373
Teacher spread0.336 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreProtocol

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations8
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueAmerican Heart JournalSame topicCardiac pacing and defibrillation studiesFrench-language works237,207